Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
The milestone of operating continuously a very complex system for over two years has demonstrated the effectiveness of integrated laboratory automation solutions
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Subscribe To Our Newsletter & Stay Updated